TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10739360

Group type: EXPERIMENTAL
Intervention: Granisetron (2 mg/m2) plus dexamethasone (8 mg/m2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ondansetron (5.3 mg/m2) plus dexamethasone (8 mg/m2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tropisetron (3.3 mg/m2) plus dexamethasone (8 mg/m2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chemotherapy with IFO
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chemotherapy with CDP/ADM
Number of subjects: 90
Study: 8959118

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1 mg day‐1
Number of subjects: 213

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 2 mg day‐1
Number of subjects: 213
Study: 1530423

Group type: EXPERIMENTAL
Intervention: 60 mg isosorbide dinitrate once daily
Number of subjects: 126

Group type: COMPARATOR
Intervention: 20 mg isosorbide dinitrate three times daily
Number of subjects: 126
Study: 6199177

Group type: EXPERIMENTAL
Intervention: Combined use of mexiletine (200 mg three times daily) and propranolol (20 mg three times daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mexiletine alone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 14
Study: 29172972

Group type: EXPERIMENTAL
Intervention: Website reporting both qualitative (patient comments) and quantitative information
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Website augmented by a decision aid (labeling of patient comments)
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Decision-aided website further augmented by the presence of a trained navigator
Number of subjects: 688

Group type: COMPARATOR
Intervention: Conventional website reporting only quantitative performance information
Number of subjects: 688
Study: 30193337

Group type: EXPERIMENTAL
Intervention: Prehabilitation (exercise and nutrition optimization)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 27222003

Group type: EXPERIMENTAL
Intervention: Handcycling training (3 × 30 min/week at 65% HRR for 7 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 22
Study: 25378931

Group type: EXPERIMENTAL
Intervention: High-H2 water containing 7 ppm H2 (3.5 mg H2 in 500 mL water)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-H2 water
Number of subjects: 26
Study: 21819594

Group type: EXPERIMENTAL
Intervention: McKenzie treatment program
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Back School treatment program
Number of subjects: 148
Study: 19248539

Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intraocular lens (IOL group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of CTR group to IOL group
Number of subjects: 20
Study: 17217664

Group type: EXPERIMENTAL
Intervention: Breastfeeding until more than 4 months of age, followed by partially hydrolyzed formula (pHF), combined with solid foods avoidance until 4 months, and avoidance of egg, fish, and shrimp until 12 months.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Breastfeeding for less than 4 months or bottle feeding with cow's milk-based formula, introduction of egg yolk at 4 months and egg white at 6 months, with no dietary avoidance.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intervention group (breastfeeding and dietary avoidance)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (less breastfeeding and no dietary avoidance)
Number of subjects: 46
Study: 14687092

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Air
Number of subjects: 16
Study: 11593067

Group type: EXPERIMENTAL
Intervention: Diuretics, digoxin, angiotensin‐converting enzyme inhibitors, beta‐blockers; specific dosages and durations not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective, randomized trials; specific details not available.
Number of subjects: 0
Study: 8988914

Group type: EXPERIMENTAL
Intervention: Vitamin A dosing
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 7903966

Group type: EXPERIMENTAL
Intervention: Imipramine (intervention group)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 85
Study: 3121055

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aerobic and strengthening exercises
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 122696

Group type: EXPERIMENTAL
Intervention: Enzyme group (mutanase and protease)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Steradent group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study: 30709402

Group type: EXPERIMENTAL
Intervention: Educational intervention designed to reduce exposure to second-hand smoke; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study: 27145447

Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Neutral Writing (NW)
Number of subjects: 277
Study: 26405990

Group type: EXPERIMENTAL
Intervention: Milkvetch root
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional clinical therapy
Number of subjects: 0
Study: 23280141

Group type: EXPERIMENTAL
Intervention: Acetazolamide (125 mg Bid, n=11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 21
Study: 22142580

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS) for mesh fixation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Titanium tacks for mesh fixation
Number of subjects: 40
Study: 19744614

Group type: EXPERIMENTAL
Intervention: hANP at 0.02 microg/kg/min from the start of cardiopulmonary bypass
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo (no hANP)
Number of subjects: 504
Study: 17196159

Group type: EXPERIMENTAL
Intervention: Individual treatment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 56
Study: 15651488

Group type: EXPERIMENTAL
Intervention: 5 mg of finasteride daily for 7 years
Number of subjects: 0
Study: 11680643

Group type: EXPERIMENTAL
Intervention: Intervention group (early caries risk assessment and preventive care)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Comparison group (historical control)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 167

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 167
Study: 9470059

Group type: EXPERIMENTAL
Intervention: Captopril (75 mg/day) plus losartan (25 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Captopril (75 mg/day) plus placebo
Number of subjects: 44
Study: 7911029

Group type: EXPERIMENTAL
Intervention: esmolol 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: esmolol 200 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 2451383

Group type: EXPERIMENTAL
Intervention: PUVA treatment, 10 systemic treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechlorethamine (HN2) treatment, 3 weeks duration
Number of subjects: 0
Study: 31994641

Group type: EXPERIMENTAL
Intervention: HIV Prevention intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health Promotion condition
Number of subjects: 0
Study: 29742924

Group type: EXPERIMENTAL
Intervention: Policosanol (POL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of Policosanol (POL) and Pentoxifylline (PTX)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal Control (NC)
Number of subjects: 30
Study: 28904061

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation (4 decaffeinated GTE capsules containing 1,315 mg total catechins, including 843 mg EGCG for 12 months)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study: 26231288

Group type: EXPERIMENTAL
Intervention: Tralokinumab every 2 weeks
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Tralokinumab every 4 weeks
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452
Study: 23393057

Group type: EXPERIMENTAL
Intervention: Telehealth intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 45
Study: 21159789

Group type: COMPARATOR
Intervention: 3.4 g/d EPA+DHA
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.85 g/d EPA+DHA
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 18500088

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (balanced salt solution)
Number of subjects: 66
Study: 16918535

Group type: EXPERIMENTAL
Intervention: Retrograde reperfusion via vena cava
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard reperfusion with anterograde simultaneous arterial and portal reperfusion
Number of subjects: 132
Study: 14971189

Group type: EXPERIMENTAL
Intervention: Walking and cycling on indoor exercise machines at a moderate intensity until 400 kcals expended, five times a week (short-bout programme)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Walking and cycling on indoor exercise machines expending 1,000 kcal per session on two days a week (long-bout programme)
Number of subjects: 30
Study: 11738778

Group type: EXPERIMENTAL
Intervention: Hypothermic group (HG) - mild hypothermia induced by a helmet device
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normothermic group (NG)
Number of subjects: 30
Study: 9421348

Group type: EXPERIMENTAL
Intervention: Milnacipran (200 mg daily for weeks 2-10, flexible dosing 100-200 mg daily for weeks 11-26)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Clomipramine (150 mg daily for weeks 2-10, flexible dosing 75-150 mg daily for weeks 11-26)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 107
Study: 8098588

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.12 mg.kg‐1; ED95 x 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Atracurium (0.4 mg.kg‐1; ED95 x 2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 18
Study: 3534583

Group type: EXPERIMENTAL
Intervention: RT + TAM (10 mg three times daily for 1 yr)
Number of subjects: 1650

Group type: COMPARATOR
Intervention: RT (postoperative radiotherapy)
Number of subjects: 1650

Group type: EXPERIMENTAL
Intervention: RT + TAM
Number of subjects: 1650

Group type: COMPARATOR
Intervention: RT
Number of subjects: 1650
Study: 29941309

Group type: EXPERIMENTAL
Intervention: Affective communication (supportive comments)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard communication (no supportive comments)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (affective and standard communication)
Number of subjects: 60
Study: 27895700

Group type: EXPERIMENTAL
Intervention: BASNEF model intervention with GATHER counselling steps
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 124
Study: 25010236

Group type: EXPERIMENTAL
Intervention: 2-hour BLS course based on computer‐assisted presentations (E1)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 2-hour BLS course practicing BLS algorithm in pairs (E2)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Self-learning BLS algorithm (C)
Number of subjects: 104
Study: 22011096

Group type: EXPERIMENTAL
Intervention: 0.016-inch coaxial superelastic nickel-titanium (NiTi)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.016-inch superelastic nickel-titanium (NiTi)
Number of subjects: 24
Study: 19929191

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 30,000 U intravenous every 48 hours for 3 doses
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) with statins
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18189169

Group type: EXPERIMENTAL
Intervention: African American elders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control for reading level achievement
Number of subjects: 0
Study: 16814646

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3491

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3491
Study: 14682110

Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte colony-stimulating factor (rhG-CSF, filgrastim [Neupogen])
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF, sargramostim [Leukine])
Number of subjects: 0
Study: 11027376

Group type: EXPERIMENTAL
Intervention: Miniplate fixation with intermaxillary fixation for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bicortical screw fixation with immediate postoperative function
Number of subjects: 30
Study: 8682519

Group type: EXPERIMENTAL
Intervention: 3D auditory display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bird's-eye-view radar display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3D auditory display + Bird's-eye-view radar display (simultaneously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tactical display only
Number of subjects: 0
Study: 1632006

Group type: EXPERIMENTAL
Intervention: District psychiatric treatment after discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 6716990

Group type: EXPERIMENTAL
Intervention: NU-CHIPS administered in noise at S/N = -4
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NU-CHIPS administered in noise at S/N = 0
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NU-CHIPS administered in noise at S/N = +2
Number of subjects: 36
Study: 31493361

Group type: EXPERIMENTAL
Intervention: Transition to a new diabetologist
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no transition)
Number of subjects: 100
Study: 28930912

Group type: EXPERIMENTAL
Intervention: ivabradine (5 mg twice daily) for 96 hours
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 70
Study: 27791067

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 954

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 954
Study: 24184410

Group type: EXPERIMENTAL
Intervention: 25g of glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucralose placebo
Number of subjects: 0
Study: 22180438

Group type: EXPERIMENTAL
Intervention: Thigh-length compression elastic stockings (CES)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Below-knee compression elastic stockings (CES)
Number of subjects: 267
Study: 20309434

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1200 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 17413473

Group type: EXPERIMENTAL
Intervention: Bryan device (Medtronic Sofamor Danek)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prestige LP device (Medtronic Sofamor Danek)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PCM device (Cervitech)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prodisc-C device (Synthes Spine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: PCM and Prodisc-C devices
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bryan and Prestige LP devices
Number of subjects: 20
Study: 15526113

Group type: EXPERIMENTAL
Intervention: 25 U botulinum toxin injected into the internal sphincter
Number of subjects: 100
Study: 12392872

Group type: EXPERIMENTAL
Intervention: Virtual colonoscopy (new procedure)
Number of subjects: 619

Group type: COMPARATOR
Intervention: Conventional colonoscopy (standard procedure)
Number of subjects: 619
Study: 10049056

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Matched unrelated donor allograft
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Bone marrow transplant (BMT)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 359

Group type: COMPARATOR
Intervention: Overall survival rate
Number of subjects: 359

Group type: COMPARATOR
Intervention: Disease-free survival
Number of subjects: 359

Group type: COMPARATOR
Intervention: Length of first remission
Number of subjects: 359
Study: 7583868

Group type: EXPERIMENTAL
Intervention: Oxatomide (60 mg daily for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2153735

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg five times daily for 5 days
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 174
Study: 6794909

Group type: EXPERIMENTAL
Intervention: HAM (hexamethylmelamine, doxorubicin, and methotrexate)
Number of subjects: 154

Group type: COMPARATOR
Intervention: CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Responders (combined HAM and CAMP)
Number of subjects: 154
Study: 31364994

Group type: EXPERIMENTAL
Intervention: Spiritual well-being (measured by the FACIT-Sp scale)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Adjustment to a stoma (measured by the Ostomy Adjustment Scale)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Quality of life (measured by the Stoma Quality of Life Scale)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Correlation between spiritual well-being and quality of life
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Correlation between spiritual well-being and adjustment to a stoma
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Correlation between quality of life and adjustment to a stoma
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Factors affecting quality of life
Number of subjects: 95
Study: 28609349

Group type: EXPERIMENTAL
Intervention: IDEAL IMPLANT Core Study
Number of subjects: 502

Group type: COMPARATOR
Intervention: Other breast implant trials (MemoryShape, Allergan 410, Sientra Core Studies)
Number of subjects: 502
Study: 26773962

Group type: EXPERIMENTAL
Intervention: Distal-type (AcuLoc(TM), Group A)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Proximal-type (VariAx(TM), Group V)
Number of subjects: 64
Study: 24635701

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 59
Study: 23173326

Group type: EXPERIMENTAL
Intervention: CMC hydrogel with EGCG
Number of subjects: 64

Group type: COMPARATOR
Intervention: CMC hydrogel (control group)
Number of subjects: 64
Study: 19803599

Group type: EXPERIMENTAL
Intervention: Therapist behaviors (teaching, focusing on strengths, making reinforcing statements, problem solving, dealing with practical family needs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapist behaviors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caregiver race, financial hardship, and therapist-caregiver racial match
Number of subjects: 0
Study: 17258718

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg/day
Number of subjects: 2587

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2587
Study: 16385106

Group type: EXPERIMENTAL
Intervention: New therapies in clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanism-based approach to treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-trial testing of underlying pain mechanisms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study designs and potential solutions
Number of subjects: 0
Study: 12236487

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid at doses of 600, 1200, and 1800 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard dose of ursodeoxycholic acid (not specified)
Number of subjects: 20
Study: 9866083

Group type: EXPERIMENTAL
Intervention: GROUP‐CBT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GROUP‐FAM
Number of subjects: 60

Group type: COMPARATOR
Intervention: WL
Number of subjects: 60
Study: 8582916

Group type: EXPERIMENTAL
Intervention: Topical RGD peptide matrix
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment with silver sulfadiazine
Number of subjects: 0
Study: 2669473

Group type: EXPERIMENTAL
Intervention: Prazosin GITS (Minipress XL) 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin GITS (Minipress XL) 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin GITS (Minipress XL) (10, 20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin GITS (Minipress XL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1175123

Group type: EXPERIMENTAL
Intervention: Intermittent courses of melphalan‐prednisone combinations
Number of subjects: 482
Study: 29794310

Group type: EXPERIMENTAL
Intervention: Cervical fusion surgery
Number of subjects: 49

Group type: COMPARATOR
Intervention: Multimodal rehabilitation
Number of subjects: 49
Study: 28625383

Group type: EXPERIMENTAL
Intervention: Watchman left atrial appendage closure device
Number of subjects: 888

Group type: COMPARATOR
Intervention: Single antiplatelet therapy or no therapy (control)
Number of subjects: 888
Study: 26348661

Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Stress Management (CBSM)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Health Promotion (HP)
Number of subjects: 74
Study: 24720242

Group type: EXPERIMENTAL
Intervention: Chaplain's offer of spiritual support
Number of subjects: 223

Group type: COMPARATOR
Intervention: Nurse's offer of spiritual support
Number of subjects: 223
Study: 20861404

Group type: EXPERIMENTAL
Intervention: Video film plus usual care
Number of subjects: 91

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 91